ポイントオブケア検査市場：製品タイプ、検査タイプ、サンプルタイプ、技術、携帯性、購入形態、用途、エンドユーザー、流通チャネル別-2025-2030年世界予測

ポイントオブケア検査市場は、2024年には328億7,000万米ドルとなり、2025年には371億3,000万米ドル、CAGR13.19%で成長し、2030年には691億7,000万米ドルに達すると予測されています。

分散型診断、高度なアッセイ、デジタルコンバージェンスがいかに臨床判断経路を再定義しているかを強調する明確な業界導入

ポイント・オブ・ケア検査は、タイムリーな臨床意思決定を患者に近づけることで、診断学の形を変え続けています。本イントロダクションでは、分散型診断、デジタル接続、治療意思決定支援の融合に重点を置きながら、POC検査エコシステムの現代的な輪郭を概説します。医療システムが迅速なトリアージ、バリュー・ベース・ケア、外来患者管理を優先する中、ポイント・オブ・ケアのモダリティは、臨床的な待ち時間を短縮し、患者体験を向上させる能力についてますます評価されるようになっています。

マルチプレックスアッセイ、接続性、ケアデリバリーモデルの進歩が、どのように分散型診断診療のシステム的変化を促しているか

ポイントオブケア検査の情勢は、テクノロジー、ケアデリバリーモデル、そして患者の期待に後押しされ、変革の時を迎えています。第一に、技術的軌跡は単分析の迅速検査から多重化されたプラットフォームと統合された分子ワークフローへと移行しており、必要な時点でより広範な診断が可能になっています。同時に、センサーの小型化とマイクロ流体集積化により、サンプル量と所要時間が短縮され、在宅および外来環境での実現可能性が高まっています。

2025年に導入された米国の関税措置がPOC検査関係者に及ぼす多面的な業務およびサプライチェーンへの影響を評価します

米国による2025年の関税・貿易措置の発動は、POC検査分野のメーカー、サプライヤー、エンドユーザーにとって複雑な影響をもたらします。コンポーネント、消耗品、完成機器に対する関税は、グローバルサプライチェーンに依存する製品の陸揚げコストを上昇させ、調達戦略や再注文のタイミングに影響を与える可能性があります。多くの機器や試薬には、複数の地域から調達された電子部品、プラスチック、精密機械加工部品が組み込まれているため、関税によるコスト上昇は、特定のサブコンポーネントの原産地によって不均一になりがちです。

製品、技術、検査タイプ、携帯性、購入形態、用途、エンドユーザー、サンプルタイプ、流通チャネルのダイナミクスを統合した包括的なセグメンテーション分析により、戦略に反映

セグメンテーションの洞察により、製品カテゴリー、検査タイプ、サンプルマトリックス、テクノロジー、携帯性オプション、購入モード、アプリケーション、エンドユーザー、流通チャネルが、どのように需要パターンと開発の優先順位を形成しているかが明らかになります。製品セグメンテーションの中では、消耗品、サービスとソフトウェア、機器と分析装置、試薬とアッセイがそれぞれ個別の意味を持っています。消耗品、アクセサリー、サービスのメンテナンスとキャリブレーション、ソフトウェアと接続性は継続的な収益源と業務の継続性を支え、ベンチトップ分析装置、分子プラットフォーム、ポータブル分析装置、リーダーとスキャナーは導入シナリオと臨床ワークフローを決定し、グルコース検査ストリップ、血液学試薬、免疫測定試薬、ラテラルフローアッセイ試薬、分子アッセイキットはアッセイ特有のサプライチェーンと品質保証の要件を促進します。

南北アメリカ、中東・アフリカ、アジア太平洋地域における地理的な違いが、POCの調達、規制、展開にどのような影響を与えるか

地域的なニュアンスは、POC検査がどのように設計され、展開され、償還されるかに大きく影響し、アメリカ、欧州、中東・アフリカ、アジア太平洋はそれぞれ異なる市場促進要因や運用上の考慮事項を示しています。南北アメリカでは、医療制度が外来患者ケアの最適化と慢性疾患管理を重視しており、診療所と自宅の両方の環境で遠隔モニタリングと迅速な心血管・代謝検査をサポートする機器と測定法に対する需要を生み出しています。この地域の流通ネットワークは、統合されたサプライチェーンと地域に密着したサービスサポートを優先しており、強力なアフターサービスと主要な電子カルテとのデータ相互運用性を実証できるメーカーが有利です。

診断エコシステム内の準備、回復力、長期的差別化を決定する戦略的競合行動とプラットフォーム重視のイノベーション

POC検査の競合情勢は、戦略的パートナーシップ、プラットフォームの差別化、機器、消耗品、ソフトウェアを組み合わせた統合ソリューションへの注力によって特徴付けられています。主要企業は、複数のアッセイ形式をサポートするモジュラープラットフォームアーキテクチャを優先し、より迅速なアッセイ展開と、消耗品の継続的需要によるライフタイムバリューの向上を可能にしています。同時に、接続性ベンダーや医療ITインテグレーターとの提携は、臨床ワークフローやポピュレーションヘルス・イニシアチブにプラグインするデータリッチな診断結果を提供するために不可欠になりつつあります。

診断薬の普及、供給の回復力、持続的な商業的差別化を確保するために、企業が実施すべき実践的で優先順位の高い戦略的動き

競争力を維持し、臨床的関連性を維持するために、業界のリーダーは、製品開発を業務上の現実や進化するケアモデルと整合させる一連の実行可能なイニシアチブを追求すべきです。第一に、相互運用性とユーザー中心のソフトウェア設計を優先し、臨床医のワークフローや電子カルテにシームレスに統合できるようにすることで、導入時の摩擦を軽減します。第二に、迅速なアッセイの拡張を可能にし、複数のサンプルタイプをサポートするモジュール式プラットフォーム戦略に投資することで、調達チームの柔軟性を高め、複数の機器フットプリントの必要性を低減します。

1次関係者インタビュー、厳密な2次調査、結論検証のためのデータの三角測量別透明で再現性のある調査アプローチ

本分析を支える調査手法は、厳密性、妥当性、再現性を確保するために設計された定性的アプローチと定量的アプローチを統合したものです。1次調査は、実際の使用事例、調達上の制約、アンメットニーズを把握するため、臨床医、検査室責任者、調達担当者、機器メーカーおよび販売業者の上級幹部との詳細なインタビューから構成されました。これらのインタビューは、臨床上の優先事項を製品要件に変換するために、施設レベルの観察とワークフロー統合ポイントの検証によって補完されました。

臨床的インパクトを実現するためには、迅速な診断アクセス、運用の弾力性、厳格な品質管理のバランスが重要であることを強調する結論的な総合結果

結論として、ポイント・オブ・ケア検査は、技術的成熟度、ケア提供モデルの変化、政策シフトが診断パスウェイを共同で再定義する変曲点にあります。分散型診断への移行は、アッセイケミストリー、小型化された装置、ソフトウエア接続性の進歩に支えられているが、この移行はまた、運用、規制、サプライチェーンの課題も提起しており、意図的な緩和が必要です。関税措置、調達嗜好の変化、地域的な規制の不均一性は、利害関係者が弾力的な調達、適応可能な製品アーキテクチャ、強固なエビデンスの生成を通じて対処しなければならない複雑性の層を追加します。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場力学

• 分散型ヘルスケア現場や救急医療における迅速かつ正確な診断の需要の増加
• 遠隔患者モニタリングと仮想ヘルスケアサービスのためのPOCTを統合した遠隔医療の拡大
• ベッドサイドで包括的な多項目分析パネルを可能にするポータブルマルチプレックス免疫測定法の普及
• 迅速なPOC感受性試験を用いた分散型抗菌薬耐性監視の拡大
• 使い捨てマイクロ流体カートリッジと再利用可能な分析装置の組み合わせにより、検査コストを削減
• 外来患者の抗凝固薬管理と投与のための患者近傍凝固および止血モニタリングの採用増加
• クラウドベースの品質管理と集中分析プラットフォームの統合により、リモートデバイスのパフォーマンスを監視
• 救急部門におけるポイントオブケア心臓バイオマーカー検査の拡大により、治療までの時間を短縮
• 低資源および人道的展開向けにカスタマイズされた耐久性の高い診断および太陽光発電POCデバイスへの投資
• 相互運用可能な無線接続規格を採用し、POC結果をEHRに安全にリアルタイムで送信

第6章 市場洞察

• ポーターのファイブフォース分析
• PESTEL分析

第7章 米国の関税の累積的な影響2025

第8章 ポイントオブケア検査市場：製品別

• 消耗品サービスとソフトウェア
  • 消耗品とアクセサリー
  • サービスメンテナンスと校正
  • ソフトウェアと接続性
• 計測機器と分析装置
  • ベンチトップアナライザー
  • 分子プラットフォーム
  • ポータブルアナライザー
  • リーダーとスキャナー
• 試薬とアッセイ
  • グルコーステストストリップ
  • 血液学試薬
  • 免疫測定試薬
  • ラテラルフローアッセイ試薬
  • 分子アッセイキット

第9章 ポイントオブケア検査市場テストの種類別

• 血液ガス
• 心臓マーカー
  • B型ナトリウム利尿ペプチド
  • トロポニン
• 包括的代謝パネル
• 薬物乱用検査
• 血液学
  • 凝固検査
    • 活性化部分トロンボプラスチン時間
    • フィブリノーゲンレベル
    • プロトロンビン時間と国際標準化比
  • 全血球数
• 感染症
  • 胃腸感染症検査
  • 呼吸器感染症検査
  • 性感染症検査
• 分子診断
• 妊娠と不妊治療
• 尿検査

第10章 ポイントオブケア検査市場サンプルタイプ別

• 血
• 鼻腔および綿棒サンプル
• 唾液
• 尿

第11章 ポイントオブケア検査市場：技術別

• バイオセンサー電気化学
• 比色分析プラットフォーム
• 免疫測定
• ラテラルフローアッセイ
  • 抗体検査
  • 抗原検査
  • マルチプレックスラテラルフロー
• マイクロ流体工学
• PCRと分子

第12章 ポイントオブケア検査市場ポータビリティ別

• ベンチトップ固定式アナライザー
• ポータブルハンドヘルドデバイス

第13章 ポイントオブケア検査市場購入方法別

• 市販の検査薬
• 処方箋に基づく検査

第14章 ポイントオブケア検査市場：用途別

• 慢性疾患管理
• 救急・重篤疾患治療
• 感染症の診断
• 職業および職場におけるテスト
• 腫瘍モニタリング
• 女性の健康

第15章 ポイントオブケア検査市場：エンドユーザー別

• 外来診療センター
• 診断検査室
• 独立型救急部門
• ホームケア
• 病院と診療所
• 救急診療センター

第16章 ポイントオブケア検査市場：流通チャネル別

• オフライン
  • 直接販売
  • 販売代理店および卸売業者
  • 小売・薬局
• オンライン

第17章 南北アメリカのポイントオブケア検査市場

• 米国
• カナダ
• メキシコ
• ブラジル
• アルゼンチン

第18章 欧州・中東・アフリカのポイントオブケア検査市場

• 英国
• ドイツ
• フランス
• ロシア
• イタリア
• スペイン
• アラブ首長国連邦
• サウジアラビア
• 南アフリカ
• デンマーク
• オランダ
• カタール
• フィンランド
• スウェーデン
• ナイジェリア
• エジプト
• トルコ
• イスラエル
• ノルウェー
• ポーランド
• スイス

第19章 アジア太平洋地域のポイントオブケア検査市場

• 中国
• インド
• 日本
• オーストラリア
• 韓国
• インドネシア
• タイ
• フィリピン
• マレーシア
• シンガポール
• ベトナム
• 台湾

第20章 競合情勢

• 市場シェア分析, 2024
• FPNVポジショニングマトリックス, 2024
• 競合分析
  • F. Hoffmann-La Roche Ltd
  • Abbott Laboratories
  • Abaxis, Inc. by Zoetis Inc
  • AccuBioTech Co., Ltd.
  • ACON Laboratories, Inc.
  • Beckman Coulter
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • CardioGenics Holdings Inc.
  • Chembio Diagnostic Systems, Inc. by Biosynex
  • Danaher Corporation
  • EKF Diagnostics Holdings
  • GE Healthcare Technologies, Inc.
  • Medtronic Plc
  • Nova Biomedical Corporation
  • OraSure Technologies, Inc.
  • Quidel Corporation
  • Radiometer Medical ApS
  • Randox Laboratories Ltd.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.

第21章 リサーチAI

第22章 リサーチ統計

第23章 リサーチコンタクト

第24章 リサーチ記事

第25章 付録

LIST OF FIGURES

• FIGURE 1. POINT OF CARE TESTING MARKET RESEARCH PROCESS
• FIGURE 2. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 3. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 4. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2030 (%)
• FIGURE 6. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 7. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2030 (%)
• FIGURE 8. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2030 (%)
• FIGURE 10. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2030 (%)
• FIGURE 12. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 13. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2024 VS 2030 (%)
• FIGURE 14. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 15. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2024 VS 2030 (%)
• FIGURE 16. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 17. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2030 (%)
• FIGURE 18. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 19. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2024 VS 2030 (%)
• FIGURE 20. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 21. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
• FIGURE 22. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 23. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 24. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 25. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2024 VS 2030 (%)
• FIGURE 26. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 27. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 28. EUROPE, MIDDLE EAST & AFRICA POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 29. ASIA-PACIFIC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
• FIGURE 30. ASIA-PACIFIC POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
• FIGURE 31. POINT OF CARE TESTING MARKET SHARE, BY KEY PLAYER, 2024
• FIGURE 32. POINT OF CARE TESTING MARKET, FPNV POSITIONING MATRIX, 2024
• FIGURE 33. POINT OF CARE TESTING MARKET: RESEARCHAI
• FIGURE 34. POINT OF CARE TESTING MARKET: RESEARCHSTATISTICS
• FIGURE 35. POINT OF CARE TESTING MARKET: RESEARCHCONTACTS
• FIGURE 36. POINT OF CARE TESTING MARKET: RESEARCHARTICLES

LIST OF TABLES

• TABLE 1. POINT OF CARE TESTING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
• TABLE 3. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2018-2024 (USD MILLION)
• TABLE 4. GLOBAL POINT OF CARE TESTING MARKET SIZE, 2025-2030 (USD MILLION)
• TABLE 5. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 6. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 7. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 8. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 9. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 10. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
• TABLE 11. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 12. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 13. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 14. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES & ACCESSORIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 15. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY REGION, 2018-2024 (USD MILLION)
• TABLE 16. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SERVICE MAINTENANCE & CALIBRATION, BY REGION, 2025-2030 (USD MILLION)
• TABLE 17. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 18. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SOFTWARE & CONNECTIVITY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 19. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
• TABLE 20. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
• TABLE 21. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 22. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 23. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 24. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 25. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 26. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 27. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 28. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 29. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 30. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY READERS & SCANNERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 31. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
• TABLE 32. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
• TABLE 33. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 34. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 35. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 36. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GLUCOSE TEST STRIPS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 37. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 38. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 39. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 40. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 41. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 42. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAY REAGENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 43. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 44. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR ASSAY KITS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 45. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
• TABLE 46. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
• TABLE 47. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 48. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
• TABLE 49. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 50. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD GASES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 51. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 52. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 53. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 54. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY B-TYPE NATRIURETIC PEPTIDE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 55. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2018-2024 (USD MILLION)
• TABLE 56. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TROPONIN, BY REGION, 2025-2030 (USD MILLION)
• TABLE 57. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
• TABLE 58. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
• TABLE 59. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 60. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPREHENSIVE METABOLIC PANEL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 61. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 62. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DRUG OF ABUSE TESTING, BY REGION, 2025-2030 (USD MILLION)
• TABLE 63. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 64. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 65. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 66. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 67. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2018-2024 (USD MILLION)
• TABLE 68. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ACTIVATED PARTIAL THROMBOPLASTIN TIME, BY REGION, 2025-2030 (USD MILLION)
• TABLE 69. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 70. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FIBRINOGEN LEVEL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 71. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY REGION, 2018-2024 (USD MILLION)
• TABLE 72. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PROTHROMBIN TIME & INTERNATIONAL NORMALIZED RATIO, BY REGION, 2025-2030 (USD MILLION)
• TABLE 73. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
• TABLE 74. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
• TABLE 75. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 76. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COMPLETE BLOOD COUNT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 77. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
• TABLE 78. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
• TABLE 79. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 80. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 81. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 82. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY GASTROINTESTINAL INFECTION TESTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 83. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 84. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RESPIRATORY INFECTION TESTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 85. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 86. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SEXUALLY TRANSMITTED INFECTION TESTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 87. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
• TABLE 88. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
• TABLE 89. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 90. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 91. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 92. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PREGNANCY & FERTILITY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 93. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 94. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINALYSIS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 95. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 96. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
• TABLE 97. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2018-2024 (USD MILLION)
• TABLE 98. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BLOOD, BY REGION, 2025-2030 (USD MILLION)
• TABLE 99. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 100. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY NASAL & SWAB SAMPLES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 101. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2018-2024 (USD MILLION)
• TABLE 102. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY SALIVA, BY REGION, 2025-2030 (USD MILLION)
• TABLE 103. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 104. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 105. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 106. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 107. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY REGION, 2018-2024 (USD MILLION)
• TABLE 108. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BIOSENSOR ELECTROCHEMICAL, BY REGION, 2025-2030 (USD MILLION)
• TABLE 109. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 110. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY COLORIMETRIC PLATFORMS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 111. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 112. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY IMMUNOASSAY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 113. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 114. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 115. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 116. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIBODY TESTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 117. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 118. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ANTIGEN TESTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 119. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY REGION, 2018-2024 (USD MILLION)
• TABLE 120. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MULTIPLEX LATERAL FLOW, BY REGION, 2025-2030 (USD MILLION)
• TABLE 121. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
• TABLE 122. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
• TABLE 123. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 124. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MICROFLUIDICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 125. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY REGION, 2018-2024 (USD MILLION)
• TABLE 126. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PCR AND MOLECULAR, BY REGION, 2025-2030 (USD MILLION)
• TABLE 127. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
• TABLE 128. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
• TABLE 129. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 130. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY BENCHTOP FIXED ANALYZERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 131. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 132. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PORTABLE HANDHELD DEVICES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 133. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
• TABLE 134. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
• TABLE 135. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 136. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OVER-THE-COUNTER TESTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 137. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 138. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY PRESCRIPTION-BASED TESTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 139. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 140. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 141. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY REGION, 2018-2024 (USD MILLION)
• TABLE 142. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY CHRONIC DISEASE MANAGEMENT, BY REGION, 2025-2030 (USD MILLION)
• TABLE 143. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 144. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY EMERGENCY AND CRITICAL CARE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 145. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 146. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE DIAGNOSIS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 147. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 148. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OCCUPATIONAL AND WORKPLACE TESTING, BY REGION, 2025-2030 (USD MILLION)
• TABLE 149. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY REGION, 2018-2024 (USD MILLION)
• TABLE 150. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONCOLOGY MONITORING, BY REGION, 2025-2030 (USD MILLION)
• TABLE 151. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY REGION, 2018-2024 (USD MILLION)
• TABLE 152. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY WOMEN HEALTH, BY REGION, 2025-2030 (USD MILLION)
• TABLE 153. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 154. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 155. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 156. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY AMBULATORY CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 157. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 158. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 159. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 160. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY FREE-STANDING EMERGENCY DEPARTMENTS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 161. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 162. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOME CARE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 163. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 164. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 165. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY REGION, 2018-2024 (USD MILLION)
• TABLE 166. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY URGENT CARE CENTERS, BY REGION, 2025-2030 (USD MILLION)
• TABLE 167. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 168. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 169. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 170. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 171. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2018-2024 (USD MILLION)
• TABLE 172. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DIRECT SALES, BY REGION, 2025-2030 (USD MILLION)
• TABLE 173. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 174. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTOR & WHOLESALE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 175. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY REGION, 2018-2024 (USD MILLION)
• TABLE 176. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY RETAIL & PHARMACY, BY REGION, 2025-2030 (USD MILLION)
• TABLE 177. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 178. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 179. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
• TABLE 180. GLOBAL POINT OF CARE TESTING MARKET SIZE, BY ONLINE, BY REGION, 2025-2030 (USD MILLION)
• TABLE 181. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 182. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
• TABLE 183. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
• TABLE 184. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
• TABLE 185. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
• TABLE 186. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
• TABLE 187. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
• TABLE 188. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
• TABLE 189. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 190. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
• TABLE 191. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
• TABLE 192. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
• TABLE 193. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
• TABLE 194. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
• TABLE 195. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
• TABLE 196. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
• TABLE 197. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
• TABLE 198. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
• TABLE 199. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 200. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
• TABLE 201. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 202. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 203. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
• TABLE 204. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
• TABLE 205. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
• TABLE 206. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
• TABLE 207. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
• TABLE 208. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
• TABLE 209. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 210. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 211. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 212. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 213. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 214. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 215. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 216. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 217. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
• TABLE 218. AMERICAS POINT OF CARE TESTING MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
• TABLE 219. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 220. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
• TABLE 221. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
• TABLE 222. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
• TABLE 223. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
• TABLE 224. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
• TABLE 225. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
• TABLE 226. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
• TABLE 227. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 228. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
• TABLE 229. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
• TABLE 230. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
• TABLE 231. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
• TABLE 232. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
• TABLE 233. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
• TABLE 234. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
• TABLE 235. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
• TABLE 236. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
• TABLE 237. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 238. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
• TABLE 239. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 240. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 241. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
• TABLE 242. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
• TABLE 243. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
• TABLE 244. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
• TABLE 245. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
• TABLE 246. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
• TABLE 247. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 248. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 249. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 250. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 251. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 252. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 253. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 254. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 255. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
• TABLE 256. UNITED STATES POINT OF CARE TESTING MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
• TABLE 257. CANADA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 258. CANADA POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
• TABLE 259. CANADA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
• TABLE 260. CANADA POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
• TABLE 261. CANADA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
• TABLE 262. CANADA POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
• TABLE 263. CANADA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
• TABLE 264. CANADA POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
• TABLE 265. CANADA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 266. CANADA POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
• TABLE 267. CANADA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
• TABLE 268. CANADA POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
• TABLE 269. CANADA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
• TABLE 270. CANADA POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
• TABLE 271. CANADA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
• TABLE 272. CANADA POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
• TABLE 273. CANADA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
• TABLE 274. CANADA POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
• TABLE 275. CANADA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 276. CANADA POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
• TABLE 277. CANADA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 278. CANADA POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 279. CANADA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
• TABLE 280. CANADA POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2025-2030 (USD MILLION)
• TABLE 281. CANADA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2018-2024 (USD MILLION)
• TABLE 282. CANADA POINT OF CARE TESTING MARKET SIZE, BY PORTABILITY, 2025-2030 (USD MILLION)
• TABLE 283. CANADA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2018-2024 (USD MILLION)
• TABLE 284. CANADA POINT OF CARE TESTING MARKET SIZE, BY MODE OF PURCHASE, 2025-2030 (USD MILLION)
• TABLE 285. CANADA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2018-2024 (USD MILLION)
• TABLE 286. CANADA POINT OF CARE TESTING MARKET SIZE, BY APPLICATION, 2025-2030 (USD MILLION)
• TABLE 287. CANADA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
• TABLE 288. CANADA POINT OF CARE TESTING MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
• TABLE 289. CANADA POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
• TABLE 290. CANADA POINT OF CARE TESTING MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
• TABLE 291. CANADA POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2018-2024 (USD MILLION)
• TABLE 292. CANADA POINT OF CARE TESTING MARKET SIZE, BY OFFLINE, 2025-2030 (USD MILLION)
• TABLE 293. MEXICO POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2018-2024 (USD MILLION)
• TABLE 294. MEXICO POINT OF CARE TESTING MARKET SIZE, BY PRODUCT, 2025-2030 (USD MILLION)
• TABLE 295. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2018-2024 (USD MILLION)
• TABLE 296. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CONSUMABLES SERVICES & SOFTWARE, 2025-2030 (USD MILLION)
• TABLE 297. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2018-2024 (USD MILLION)
• TABLE 298. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INSTRUMENTS & ANALYZERS, 2025-2030 (USD MILLION)
• TABLE 299. MEXICO POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2018-2024 (USD MILLION)
• TABLE 300. MEXICO POINT OF CARE TESTING MARKET SIZE, BY REAGENTS & ASSAYS, 2025-2030 (USD MILLION)
• TABLE 301. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2018-2024 (USD MILLION)
• TABLE 302. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TEST TYPE, 2025-2030 (USD MILLION)
• TABLE 303. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2018-2024 (USD MILLION)
• TABLE 304. MEXICO POINT OF CARE TESTING MARKET SIZE, BY CARDIAC MARKERS, 2025-2030 (USD MILLION)
• TABLE 305. MEXICO POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2018-2024 (USD MILLION)
• TABLE 306. MEXICO POINT OF CARE TESTING MARKET SIZE, BY HEMATOLOGY, 2025-2030 (USD MILLION)
• TABLE 307. MEXICO POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2018-2024 (USD MILLION)
• TABLE 308. MEXICO POINT OF CARE TESTING MARKET SIZE, BY COAGULATION TESTS, 2025-2030 (USD MILLION)
• TABLE 309. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2018-2024 (USD MILLION)
• TABLE 310. MEXICO POINT OF CARE TESTING MARKET SIZE, BY INFECTIOUS DISEASE, 2025-2030 (USD MILLION)
• TABLE 311. MEXICO POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2018-2024 (USD MILLION)
• TABLE 312. MEXICO POINT OF CARE TESTING MARKET SIZE, BY SAMPLE TYPE, 2025-2030 (USD MILLION)
• TABLE 313. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2018-2024 (USD MILLION)
• TABLE 314. MEXICO POINT OF CARE TESTING MARKET SIZE, BY TECHNOLOGY, 2025-2030 (USD MILLION)
• TABLE 315. MEXICO POINT OF CARE TESTING MARKET SIZE, BY LATERAL FLOW ASSAYS, 2018-2024 (USD MILLION)
• TABLE 316. ME

The Point of Care Testing Market was valued at USD 32.87 billion in 2024 and is projected to grow to USD 37.13 billion in 2025, with a CAGR of 13.19%, reaching USD 69.17 billion by 2030.

A clear industry introduction highlighting how decentralized diagnostics, advanced assays, and digital convergence are redefining clinical decision pathways

Point of care testing continues to reshape diagnostics by bringing timely clinical decision-making closer to the patient. This introduction outlines the contemporary contours of the point of care testing ecosystem, emphasizing the convergence of decentralized diagnostics, digital connectivity, and therapeutic decision support. As health systems prioritize faster triage, value-based care, and outpatient management, point of care modalities are increasingly evaluated for their capacity to reduce clinical latency and improve patient experience.

Advances in miniaturized instrumentation, assay chemistry, and molecular methods now permit a broader range of analytes to be tested outside central laboratories. At the same time, software and connectivity tools are maturing to facilitate result integration with electronic health records and telehealth workflows. These developments are encouraging new use cases within emergency care, chronic disease monitoring, and community screening programs. Consequently, stakeholders across the value chain are recalibrating product development, reimbursement strategies, and distribution models to support rapid adoption while ensuring quality and regulatory compliance.

How converging advances in multiplexed assays, connectivity, and care delivery models are driving systemic change in decentralized diagnostic practice

The landscape of point of care testing is undergoing transformative shifts driven by technology, care delivery models, and patient expectations. First, the technological trajectory is moving from single-analyte rapid tests toward multiplexed platforms and integrated molecular workflows, enabling broader diagnostic breadth at the point of need. Concurrently, sensor miniaturization and microfluidic integration are reducing sample volume and turnaround time, which enhances feasibility for home and ambulatory environments.

Second, care delivery models are evolving: outpatient and community settings are absorbing responsibilities historically held by centralized laboratories, and telemedicine interfaces increasingly rely on near-real-time diagnostics to inform remote consultations. Third, the role of software and connectivity has intensified, with interoperability and cybersecurity becoming prerequisites for clinical adoption. Regulatory pathways are also adapting to accommodate decentralized diagnostics, creating opportunities as well as expectations for robust quality management systems. Finally, patient-centric trends-such as convenience, rapid reassurance, and longitudinal monitoring-are reshaping product design priorities, emphasizing user experience, simplified workflows, and clear result interpretation. Together, these shifts are not incremental but collectively redefine procurement decisions, clinical pathways, and competitive positioning across the ecosystem.

Assessing the multifaceted operational and supply chain consequences of United States tariff measures introduced in 2025 on point of care testing stakeholders

The imposition of tariffs and trade measures by the United States in 2025 introduces a complex set of effects for manufacturers, suppliers, and end users in the point of care testing space. Tariffs on components, consumables, and finished devices can elevate landed costs for products that rely on global supply chains, thereby influencing procurement strategies and reorder cadence. Since many instruments and reagents incorporate electronic components, plastics, and precision machined parts sourced from multiple geographies, tariff-driven cost escalation tends to be uneven and dependent on the origin of specific subcomponents.

In response to tariff pressures, manufacturers may accelerate regional sourcing strategies, increase vertical integration of critical elements, or relocate certain production activities to tariff-favored jurisdictions. These operational adjustments can mitigate exposure but often require near-term capital and redesign efforts. For healthcare providers and distributors, the cumulative effect of tariffs can shift purchasing towards products with more stable supply chain footprints, local assembly, or alternative suppliers offering comparable clinical performance. Pricing adjustments may also influence inventory policies, with stakeholders maintaining higher safety stocks to buffer against potential re-pricing or delays. Importantly, the regulatory and quality assurance implications of sourcing changes necessitate careful validation to ensure clinical equivalence, so organizations must balance cost-containment with the need to preserve test accuracy and continuity of care.

Comprehensive segmentation analysis uniting product, technology, test type, portability, purchase mode, application, end user, sample type, and distribution channel dynamics to inform strategy

Segmentation insights reveal how distinct product categories, test types, sample matrices, technologies, portability options, purchase modes, applications, end users, and distribution channels shape demand patterns and development priorities. Within product segmentation, consumables, services and software, instruments and analyzers, and reagents and assays each carry discrete implications: consumables, accessories and service maintenance and calibration, and software and connectivity underpin ongoing revenue streams and operational continuity; benchtop analyzers, molecular platforms, portable analyzers, and readers and scanners determine deployment scenarios and clinical workflows; while glucose test strips, hematology reagents, immunoassay reagents, lateral flow assay reagents, and molecular assay kits drive assay-specific supply chain and quality assurance requirements.

When viewed through test-type segmentation, the breadth from blood gases to infectious disease and molecular diagnostics affects instrument selection and clinician training, with cardiac markers and hematology requiring specialized assay robustness and coagulation testing demanding precise calibration and control across activated partial thromboplastin time, fibrinogen level, and prothrombin time and international normalized ratio assays. Infectious disease testing spans gastrointestinal, respiratory, and sexually transmitted infection panels, each influencing throughput needs and biosafety considerations. Sample-type segmentation, including blood, nasal and swab samples, saliva, and urine, informs collection device design, patient acceptability, and pre-analytical stability requirements. Technology segmentation differentiates biosensor electrochemical approaches, colorimetric platforms, immunoassays, lateral flow assays-spanning antibody, antigen, and multiplex formats-microfluidics, and PCR and molecular technologies, with each imparting trade-offs between sensitivity, specificity, cost, and operational complexity.

Portability options distinguish benchtop fixed analyzers from portable handheld devices, aligning device footprint with intended point of care settings. Mode of purchase segmentation separates over-the-counter accessibility from prescription-based dispensing, shaping labeling, user instructions, and post-market surveillance obligations. Application-driven segmentation-from chronic disease management to emergency and critical care, infectious disease diagnosis, occupational testing, oncology monitoring, and women's health-dictates performance thresholds and integration requirements with clinical care pathways. End-user segmentation that includes ambulatory care centers, diagnostic laboratories, free-standing emergency departments, home care, hospitals and clinics, and urgent care centers emphasizes differences in staffing, regulatory oversight, and capital acquisition processes. Finally, distribution channel segmentation across offline and online pathways, with offline methods such as direct sales, distributor and wholesale, and retail and pharmacy, impacts go-to-market strategies, margin structures, and customer support models. Taken together, these segmentation lenses provide a multifaceted view that guides product roadmaps, commercialization priorities, and lifecycle planning.

How geographic differences across the Americas, Europe Middle East and Africa, and Asia-Pacific shape procurement, regulation, and deployment of point of care diagnostics

Regional nuances significantly influence how point of care testing is designed, deployed, and reimbursed, with the Americas, Europe, Middle East and Africa, and Asia-Pacific each presenting distinct market drivers and operational considerations. In the Americas, health systems emphasize outpatient care optimization and chronic disease management, creating demand for devices and assays that support remote monitoring and rapid cardiovascular and metabolic testing in both clinic and home settings. Distribution networks in this region prioritize integrated supply chains and localized service support, which favors manufacturers that can demonstrate robust after-sales service and data interoperability with dominant electronic health records.

Europe, Middle East and Africa exhibit heterogeneity in regulatory regimes and healthcare infrastructure, with pockets of high regulatory rigor coexisting with areas where access barriers remain. This diversity requires adaptable product configurations and flexible pricing models. Interoperability standards and data privacy frameworks are especially influential in regulatory decision-making and clinical adoption in Europe, while capacity building and decentralized solutions are prioritized in many parts of the Middle East and Africa. In Asia-Pacific, rapid urbanization, expanding primary care networks, and high-volume public health screening initiatives drive demand for scalable, cost-effective point of care solutions. Regional manufacturing capabilities and supplier ecosystems in Asia-Pacific often accelerate product iteration cycles, and partnerships with local distributors are critical to achieve penetration across varied healthcare settings. Across all regions, reimbursement pathways, regulatory timelines, and customer training imperatives shape adoption velocity and product design choices.

Strategic competitive behaviors and platform-focused innovation that determine preparedness, resilience, and long-term differentiation within the diagnostic ecosystem

Competitive dynamics within the point of care testing landscape are characterized by strategic partnerships, platform differentiation, and a focus on integrated solutions that combine instruments, consumables, and software. Leading companies are prioritizing modular platform architectures that support multiple assay formats, enabling faster assay rollouts and improved lifetime value through recurring consumable demand. Concurrently, alliances with connectivity vendors and health IT integrators are becoming essential to deliver data-rich diagnostic results that plug into clinical workflows and population health initiatives.

Innovation strategies vary by firm, with some investing heavily in molecular and microfluidic technologies to expand the diagnostic menu, while others concentrate on low-cost lateral flow and biosensor technologies optimized for point-of-care ease of use. Service offerings, including field maintenance, calibration, and software updates, are being redefined as a competitive differentiator, and companies that can demonstrate rapid support turnaround and robust quality systems tend to secure larger institutional contracts. Supply chain resilience and localized manufacturing capabilities have also risen in strategic importance, prompting acquisitions and joint ventures to reduce exposure to global logistics disruptions. Finally, commercial models are shifting toward subscription and outcomes-based arrangements in select accounts, aligning vendor incentives with clinical performance and operational uptime.

Practical and prioritized strategic moves that companies should implement to secure adoption, supply resilience, and sustained commercial differentiation in diagnostics

To remain competitive and clinically relevant, industry leaders should pursue a set of actionable initiatives that align product development with operational realities and evolving care models. First, prioritize interoperability and user-centered software design so that devices integrate seamlessly into clinician workflows and electronic health records, thereby reducing friction at the point of adoption. Second, invest in modular platform strategies that allow rapid assay expansion and support multiple sample types, which increases flexibility for procurement teams and reduces the need for multiple device footprints.

Third, strengthen supply chain resilience through strategic regional sourcing, dual sourcing of critical components, and validated local assembly where feasible, which mitigates exposure to trade disruptions and tariff-driven cost pressures. Fourth, enhance post-market service offerings-particularly field maintenance and remote diagnostics-to preserve instrument uptime and protect clinical continuity. Fifth, adopt evidence-generation strategies that emphasize real-world performance, workflow impact, and patient-centric outcomes, thereby supporting payer discussions and clinical adoption. Finally, explore alternative commercial models, such as managed service agreements or outcome-linked contracts, to better align with healthcare purchasers' objectives and to create predictable revenue streams. Executing these actions with clear accountability and staged milestones will help firms convert technical capabilities into durable market advantage.

A transparent and reproducible research approach combining primary stakeholder interviews, rigorous secondary review, and data triangulation to validate conclusions

The research methodology underpinning this analysis integrates qualitative and quantitative approaches designed to ensure rigor, relevance, and reproducibility. Primary research consisted of in-depth interviews with clinicians, laboratory directors, procurement officers, and senior executives across device manufacturers and distributors to capture real-world use cases, procurement constraints, and unmet needs. These interviews were complemented by facility-level observations and validation of workflow integration points to translate clinical priorities into product requirements.

Secondary research included a systematic review of peer-reviewed clinical literature, regulatory guidance documents, industry standards for quality management and interoperability, and technical white papers describing assay and platform performance. Data triangulation techniques were employed to reconcile insights from diverse sources and to validate assumptions about operational behaviors and adoption barriers. The research also applied scenario analysis to assess supply chain risk and regulatory sensitivity, and key findings were stress-tested through expert panels to refine recommendations. Throughout, the methodology emphasized transparency, with audit trails linking conclusions to source materials and interview excerpts, ensuring that stakeholders can trace analytic judgments back to empirical evidence.

A conclusive synthesis emphasizing the balance between rapid diagnostic access, operational resilience, and rigorous quality controls to realize clinical impact

In conclusion, point of care testing is at an inflection point where technological maturity, changing care delivery models, and policy shifts are jointly redefining diagnostic pathways. The move toward decentralized diagnostics is supported by advances in assay chemistry, miniaturized instrumentation, and software connectivity, yet this transition also raises operational, regulatory, and supply chain challenges that require deliberate mitigation. Tariff actions, shifting procurement preferences, and regional regulatory heterogeneity add layers of complexity that stakeholders must address through resilient sourcing, adaptable product architectures, and robust evidence generation.

For manufacturers, the imperative is to deliver clinically rigorous, easy-to-use platforms that integrate seamlessly into workflows while offering sustainable service and supply models. For providers and payers, the focus should be on harnessing point of care capabilities to improve decision latency and patient experience without sacrificing quality controls. By aligning technology investments, commercial models, and implementation frameworks, stakeholders can realize the promise of point of care testing to deliver meaningful improvements in clinical care and operational efficiency.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

• 4.1. Introduction
• 4.2. Market Sizing & Forecasting

5. Market Dynamics

• 5.1. Increasing demand for rapid, accurate diagnostics in decentralized healthcare settings and urgent care
• 5.2. Expansion of telemedicine integrating POCT for remote patient monitoring and virtual healthcare services
• 5.3. Proliferation of portable multiplex immunoassays enabling comprehensive multi-analyte panels at bedside
• 5.4. Growth of decentralized antimicrobial resistance surveillance using rapid point of care susceptibility testing assays
• 5.5. Emergence of disposable microfluidic cartridges paired with reusable analyzers to drive down per test costs
• 5.6. Increased adoption of near-patient coagulation and hemostasis monitoring for outpatient anticoagulant management and dosing
• 5.7. Integration of cloud-based quality control and centralized analytics platforms for remote device performance monitoring
• 5.8. Scaling of point of care cardiac biomarker testing in emergency departments to reduce door to treatment times
• 5.9. Investment in ruggedized diagnostics and solar powered POC devices tailored for low-resource and humanitarian deployments
• 5.10. Adoption of interoperable wireless connectivity standards to enable secure real-time transmission of POC results to EHRs

6. Market Insights

• 6.1. Porter's Five Forces Analysis
• 6.2. PESTLE Analysis

7. Cumulative Impact of United States Tariffs 2025

8. Point of Care Testing Market, by Product

• 8.1. Introduction
• 8.2. Consumables Services & Software
  • 8.2.1. Consumables & Accessories
  • 8.2.2. Service Maintenance & Calibration
  • 8.2.3. Software & Connectivity
• 8.3. Instruments & Analyzers
  • 8.3.1. Benchtop Analyzers
  • 8.3.2. Molecular Platforms
  • 8.3.3. Portable Analyzers
  • 8.3.4. Readers & Scanners
• 8.4. Reagents & Assays
  • 8.4.1. Glucose Test Strips
  • 8.4.2. Hematology Reagents
  • 8.4.3. Immunoassay Reagents
  • 8.4.4. Lateral Flow Assay Reagents
  • 8.4.5. Molecular Assay Kits

9. Point of Care Testing Market, by Test Type

• 9.1. Introduction
• 9.2. Blood Gases
• 9.3. Cardiac Markers
  • 9.3.1. B-type Natriuretic Peptide
  • 9.3.2. Troponin
• 9.4. Comprehensive Metabolic Panel
• 9.5. Drug Of Abuse Testing
• 9.6. Hematology
  • 9.6.1. Coagulation Tests
    • 9.6.1.1. Activated Partial Thromboplastin Time
    • 9.6.1.2. Fibrinogen Level
    • 9.6.1.3. Prothrombin Time & International Normalized Ratio
  • 9.6.2. Complete Blood Count
• 9.7. Infectious Disease
  • 9.7.1. Gastrointestinal Infection Tests
  • 9.7.2. Respiratory Infection Tests
  • 9.7.3. Sexually Transmitted Infection Tests
• 9.8. Molecular Diagnostics
• 9.9. Pregnancy & Fertility
• 9.10. Urinalysis

10. Point of Care Testing Market, by Sample Type

• 10.1. Introduction
• 10.2. Blood
• 10.3. Nasal & Swab Samples
• 10.4. Saliva
• 10.5. Urine

11. Point of Care Testing Market, by Technology

• 11.1. Introduction
• 11.2. Biosensor Electrochemical
• 11.3. Colorimetric Platforms
• 11.4. Immunoassay
• 11.5. Lateral Flow Assays
  • 11.5.1. Antibody Tests
  • 11.5.2. Antigen Tests
  • 11.5.3. Multiplex Lateral Flow
• 11.6. Microfluidics
• 11.7. PCR And Molecular

12. Point of Care Testing Market, by Portability

• 12.1. Introduction
• 12.2. Benchtop Fixed Analyzers
• 12.3. Portable Handheld Devices

13. Point of Care Testing Market, by Mode of Purchase

• 13.1. Introduction
• 13.2. Over-The-Counter Tests
• 13.3. Prescription-Based Tests

14. Point of Care Testing Market, by Application

• 14.1. Introduction
• 14.2. Chronic Disease Management
• 14.3. Emergency And Critical Care
• 14.4. Infectious Disease Diagnosis
• 14.5. Occupational And Workplace Testing
• 14.6. Oncology Monitoring
• 14.7. Women Health

15. Point of Care Testing Market, by End User

• 15.1. Introduction
• 15.2. Ambulatory Care Centers
• 15.3. Diagnostic Laboratories
• 15.4. Free-Standing Emergency Departments
• 15.5. Home Care
• 15.6. Hospitals & Clinics
• 15.7. Urgent Care Centers

16. Point of Care Testing Market, by Distribution Channel

• 16.1. Introduction
• 16.2. Offline
  • 16.2.1. Direct Sales
  • 16.2.2. Distributor & Wholesale
  • 16.2.3. Retail & Pharmacy
• 16.3. Online

17. Americas Point of Care Testing Market

• 17.1. Introduction
• 17.2. United States
• 17.3. Canada
• 17.4. Mexico
• 17.5. Brazil
• 17.6. Argentina

18. Europe, Middle East & Africa Point of Care Testing Market

• 18.1. Introduction
• 18.2. United Kingdom
• 18.3. Germany
• 18.4. France
• 18.5. Russia
• 18.6. Italy
• 18.7. Spain
• 18.8. United Arab Emirates
• 18.9. Saudi Arabia
• 18.10. South Africa
• 18.11. Denmark
• 18.12. Netherlands
• 18.13. Qatar
• 18.14. Finland
• 18.15. Sweden
• 18.16. Nigeria
• 18.17. Egypt
• 18.18. Turkey
• 18.19. Israel
• 18.20. Norway
• 18.21. Poland
• 18.22. Switzerland

19. Asia-Pacific Point of Care Testing Market

• 19.1. Introduction
• 19.2. China
• 19.3. India
• 19.4. Japan
• 19.5. Australia
• 19.6. South Korea
• 19.7. Indonesia
• 19.8. Thailand
• 19.9. Philippines
• 19.10. Malaysia
• 19.11. Singapore
• 19.12. Vietnam
• 19.13. Taiwan

20. Competitive Landscape

• 20.1. Market Share Analysis, 2024
• 20.2. FPNV Positioning Matrix, 2024
• 20.3. Competitive Analysis
  • 20.3.1. F. Hoffmann-La Roche Ltd
  • 20.3.2. Abbott Laboratories
  • 20.3.3. Abaxis, Inc. by Zoetis Inc
  • 20.3.4. AccuBioTech Co., Ltd.
  • 20.3.5. ACON Laboratories, Inc.
  • 20.3.6. Beckman Coulter
  • 20.3.7. Becton, Dickinson and Company
  • 20.3.8. Bio-Rad Laboratories, Inc.
  • 20.3.9. bioMerieux SA
  • 20.3.10. CardioGenics Holdings Inc.
  • 20.3.11. Chembio Diagnostic Systems, Inc. by Biosynex
  • 20.3.12. Danaher Corporation
  • 20.3.13. EKF Diagnostics Holdings
  • 20.3.14. GE Healthcare Technologies, Inc.
  • 20.3.15. Medtronic Plc
  • 20.3.16. Nova Biomedical Corporation
  • 20.3.17. OraSure Technologies, Inc.
  • 20.3.18. Quidel Corporation
  • 20.3.19. Radiometer Medical ApS
  • 20.3.20. Randox Laboratories Ltd.
  • 20.3.21. Siemens Healthineers AG
  • 20.3.22. Thermo Fisher Scientific Inc.

21. ResearchAI

22. ResearchStatistics

23. ResearchContacts

24. ResearchArticles

25. Appendix